GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Windtree Therapeutics
Windtree is a biopharmaceutical company specializing in the treatment of cardiovascular diseases. Its stock price is highly volatile and driven by news about clinical trials of its drugs.
Share prices of companies in the market segment - Heart
Windtree Therapeutics is a biopharmaceutical company developing drugs to treat cardiovascular diseases in the critical care setting. We've categorized it as a "Heart" company. The chart below shows how investors value companies in the critical care field.
Broad Market Index - GURU.Markets
Windtree Therapeutics is a biotech company developing drugs to treat cardiovascular diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Windtree shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
WINT - Daily change in the company's share price Windtree Therapeutics
For Windtree Therapeutics, Inc., a cardiology company, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risk in this niche.
Daily change in the price of a set of shares in a market segment - Heart
Windtree Therapeutics is a biopharmaceutical company developing drugs to treat critical cardiovascular diseases. Cardiology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Windtree is a biotech company specializing in the treatment of cardiovascular diseases. Given the prevalence of these diseases, its developments are attracting attention. Its shares are volatile and dependent on research progress, contributing to market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Windtree Therapeutics
Windtree Therapeutics' year-to-date performance is a story about its cardiovascular drug development. Its 12-month market cap depends entirely on clinical trial data. Success with its lead candidate, which aims to improve cardiac function in cardiogenic shock, could be a breakthrough.
Annual dynamics of market capitalization of the market segment - Heart
Windtree, a late-stage biotech company, develops drugs for the treatment of cardiovascular diseases. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Windtree Therapeutics, a biopharmaceutical company focused on treating cardiovascular diseases, is betting on the success of its clinical programs. Its year-over-year market capitalization doesn't reflect the state of the economy, but rather demonstrates investors' faith in its scientific developments and future drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Windtree Therapeutics
Windtree is a biopharmaceutical company focused on treating cardiovascular diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its flagship programs is the primary driver.
Monthly dynamics of market capitalization of the market segment - Heart
Windtree Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of acute cardiovascular and pulmonary diseases. The chart below shows the overall dynamics of the biotech sector, where the company occupies the critical care niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Windtree Therapeutics is a biotech company whose value is tied to the success of its cardiology developments. The chart below shows that the company's monthly share price fluctuations are not related to overall market movements, but rather reflect investor expectations regarding clinical trial results.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Windtree Therapeutics
Windtree Therapeutics, a biopharmaceutical company focused on treating cardiovascular and pulmonary diseases, exhibits high volatility. Weekly stock performance depends on news about clinical trials, where any event can dramatically alter the company's outlook.
Weekly dynamics of market capitalization of the market segment - Heart
Windtree Therapeutics shares, like those of the entire cardiac biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Windtree Therapeutics is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that WINT's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
WINT - Market capitalization of the company Windtree Therapeutics
The Windtree Therapeutics chart is a financial map of critical care. The market cap of this company, which develops drugs to treat cardiogenic shock and other critical conditions, reflects the hopes for its innovations. Its volatility mirrors the complex clinical trials where the lives of patients in intensive care are at stake.
WINT - Share of the company's market capitalization Windtree Therapeutics within the market segment - Heart
Windtree Therapeutics specializes in the treatment of acute cardiovascular and pulmonary diseases. The company's market capitalization in the biopharmaceutical sector reflects the potential of its critical care developments. Windtree's market capitalization reflects its ability to develop life-saving drugs in critical situations.
Market capitalization of the market segment - Heart
Windtree Therapeutics develops drugs to treat cardiovascular diseases. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which Windtree is seeking new approaches to treating heart disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
Windtree Therapeutics is a biotech company focused on treating cardiovascular diseases in the critical care setting. Its market cap chart tells the story of saving lives in critical situations. Its value reflects the potential of its drugs for emergency medicine.
Book value capitalization of the company, segment and market as a whole
WINT - Book value capitalization of the company Windtree Therapeutics
Windtree Therapeutics is a biopharmaceutical company. Its book value represents its R&D capital. The chart below shows its financial resources for developing critical care drugs. This level is an indicator of its ability to fund its research programs.
WINT - Share of the company's book capitalization Windtree Therapeutics within the market segment - Heart
Windtree Therapeutics is a clinical-stage biotech company developing drugs for the treatment of cardiovascular diseases. Its value lies in its scientific platform. Its tangible asset share schedule will be minimal, as is typical for R&D companies.
Market segment balance sheet capitalization - Heart
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Windtree, which develops drugs for cardiovascular diseases, looks "light." Its value lies in its patents and scientific data, not in its large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Windtree Therapeutics develops drugs to treat cardiorespiratory diseases. The company's assets are not hospitals, but patents and clinical trial data. The company's balance sheet is the cost of trying to create new tools to save people in critical conditions, such as cardiogenic shock.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Windtree Therapeutics
Windtree's balance sheet consists of its cash and patents. A market capitalization close to this cash value shows that investors have little faith in the success of its drugs after a series of failures. The MvsBCap_Co chart ≈ 1 represents the company's valuation as a "piggy bank," where the scientific "dream" is worth next to nothing.
Market to book capitalization ratio in a market segment - Heart
Windtree Therapeutics is a biotech company specializing in drugs for the treatment of cardiovascular diseases in critical care settings. The chart shows the speculative valuation of its developments, which is dependent on the results of clinical trials.
Market to book capitalization ratio for the market as a whole
Windtree Therapeutics develops treatments for cardiovascular diseases. The company's market capitalization depends almost entirely on the success of its clinical trials. This metric demonstrates the high level of investor expectations. A significant premium to the market valuation over the book value indicates confidence in the breakthrough potential of the drugs being developed.
Debts of the company, segment and market as a whole
WINT - Company debts Windtree Therapeutics
Windtree Therapeutics, a company developing treatments for cardiovascular diseases, uses debt to finance its clinical programs. This chart shows how the company raises capital to advance its drug candidates through late-stage development. In the biotech world, debt is the bridge between clinical data and potential market entry.
Market segment debts - Heart
Windtree Therapeutics is a biopharmaceutical company specializing in drugs for the treatment of acute cardiovascular diseases. Developing drugs for acute care has its own unique challenges. This chart shows how the company funds its expensive clinical-stage research in this critical area.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Windtree Therapeutics
Windtree Therapeutics is a biopharmaceutical company developing drugs for cardiovascular disease. This chart shows how much it relies on external funding to conduct clinical trials. It reflects the high financial risk inherent in companies seeking to bring new drugs to market in this critical area.
Market segment debt to market segment book capitalization - Heart
Windtree Therapeutics is a biotech company specializing in the development of drugs for the treatment of acute cardiovascular and pulmonary diseases. This is critical care medicine. The chart shows how the company's debt load for funding trials compares to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
Windtree Therapeutics (WINT) is a biopharmaceutical company developing treatments for critical cardiovascular diseases. This chart shows the overall debt burden of the economy. It provides a backdrop for understanding why WINT relies on equity capital during clinical trials, avoiding debt risk until commercialization.
P/E of the company, segment and market as a whole
P/E - Windtree Therapeutics
This chart shows the valuation of Windtree Therapeutics, a biopharmaceutical company focused on treating cardiovascular diseases. There is no P/E ratio. The company's valuation is a bet on the success of its drugs in clinical trials. The chart is highly sensitive to research news and regulatory decisions.
P/E of the market segment - Heart
This chart shows the average P/E for biotech companies. For Windtree Therapeutics, which focuses on cardiovascular diseases, it serves as a backdrop. It shows the overall level of optimism in the sector, providing context for Windtree's valuation, which is betting on the success of its drugs in clinical trials.
P/E of the market as a whole
Windtree Therapeutics develops drugs to treat critical conditions in cardiology and pulmonology, such as cardiogenic shock. This is an area with significant unmet need. This chart shows biotech sentiment. It helps understand how the market views the potential of the company's drugs to save lives in emergency situations and the level of risk they factor into its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Windtree Therapeutics
Windtree Therapeutics is a biotech company developing treatments for cardiovascular diseases. For a clinical-stage company, this chart serves as a barometer of expectations. It reflects analysts' assessments of the likelihood of success for its key drugs in trials and their potential future market demand.
%20P%2FE%20Windtree%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Windtree-Therapeutics&v=1772513554917 "Chart of the company's future (projected) P/E Windtree Therapeutics")
Future (projected) P/E of the market segment - Heart
Windtree Therapeutics, Inc. develops drugs to treat cardiovascular diseases, particularly cardiogenic shock. This chart shows average expectations for the pharmaceutical sector. WINT's position may indicate the extent to which investors believe in the potential of its drugs to treat critical conditions, where there is a high unmet medical need.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772513554934 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Windtree Therapeutics develops treatments for cardiovascular diseases. The company's success depends entirely on clinical trial results and regulatory approvals. The overall market sentiment reflected in this chart is secondary to news about its medical developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513554944 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Windtree Therapeutics
Windtree Therapeutics is a biotech company focused on developing treatments for cardiovascular and respiratory diseases in critical care. This graph shows the development pipeline for critical care medications. The losses reflect R&D costs, while future profits depend on the success and approval of its critical care medications.
Profit of companies in the market segment - Heart
Windtree Therapeutics develops treatments for acute cardiovascular diseases. Profitability in this sector, as this chart shows, is driven by the need for effective medications for emergency situations, such as cardiogenic shock. For WINT, success depends on clinical trial results demonstrating that their drugs save lives in critical conditions.
Overall market profit
Windtree Therapeutics, a biopharmaceutical company focused on critical cardiovascular care, addresses critical medical needs. Demand for its lifesaving drugs is unaffected by economic cycles, as this chart illustrates. The company's success is determined by drug efficacy and regulatory approval.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Windtree Therapeutics
Windtree Therapeutics develops drugs to treat cardiovascular and respiratory diseases. This chart reflects analyst forecasts, which are bets on the success of its clinical trials. It represents the financial expression of hopes that its drugs will help critically ill patients.
%20profit%20of%20the%20company%20Windtree%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Windtree-Therapeutics&v=1772513555026 "Graph of future (projected) profit of the company Windtree Therapeutics")
Future (predicted) profit of companies in the market segment - Heart
Windtree Therapeutics develops treatments for acute cardiovascular and pulmonary diseases. The company's products are designed for use in intensive care settings. This chart shows the revenue forecast for the cardiac sector, reflecting the need for new, effective drugs for critical conditions such as cardiogenic shock.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772513555060 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Windtree Therapeutics is a biotech company developing drugs to treat cardiovascular diseases. Its success depends entirely on the results of clinical trials. The overall economic outlook, reflected in the chart, affects the company indirectly through investors' willingness to finance long-term and risky biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513555078 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Windtree Therapeutics
Windtree Therapeutics is a biotech company focused on critical care medications for acute cardiovascular and pulmonary diseases. It has no commercial revenue. The chart reflects investor assessments of its clinical development pipeline. This is a bet that its drugs can save lives in critical situations.
P/S market segment - Heart
Windtree Therapeutics develops treatments for cardiovascular diseases, particularly critical conditions such as cardiogenic shock. The chart shows the average revenue estimate for the biotech company, allowing investors to gauge the potential of its drugs to save lives in critical situations.
P/S of the market as a whole
Windtree Therapeutics develops drugs to treat critical cardiovascular conditions, such as cardiogenic shock. The company targets the intensive care niche. The graph of average market revenue estimates helps understand the market's expectations for commercial success in the hospital segment, which are factored into its current valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Windtree Therapeutics
Windtree Therapeutics is a biotech company specializing in critical care medications for respiratory and cardiovascular diseases. This chart visualizes investor expectations for its developments, valuing the company based on potential future revenue from its critical care medications.
%20P%2FS%20Windtree%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Windtree-Therapeutics&v=1772513555222 "The graph of the company's future (projected) P/S Windtree Therapeutics")
Future (projected) P/S of the market segment - Heart
Windtree Therapeutics is a biotech company developing drugs to treat cardiovascular diseases, particularly congestive heart failure. This figure shows the median future revenue estimates for cardiology companies. This helps gauge how highly investors value the potential of Windtree's drugs to address urgent medical needs.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772513555230 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Windtree Therapeutics develops treatments for acute cardiovascular diseases. This market has a high unmet need. This overall revenue expectation graph is irrelevant. WINT's success depends solely on the results of clinical trials and regulatory approvals for its innovative drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513555242 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Windtree Therapeutics
Windtree Therapeutics is a biotech company specializing in the development of treatments for heart and lung diseases. Being in the clinical stage, it typically does not generate sales revenue. Any revenue reflected in this chart likely comes from licensing agreements or development partnerships.
Sales of companies in the market segment - Heart
Windtree Therapeutics is a biotech company developing treatments for cardiovascular diseases, particularly acute heart failure and cardiogenic shock. Their drugs are aimed at improving cardiac function in critical situations. This chart shows the total revenue in the sector, reflecting the need for new treatments for acute cardiac conditions.
Overall market sales
Windtree Therapeutics is a biotech company specializing in drugs for the treatment of critical cardiovascular diseases. Its success depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences the investment climate in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Windtree Therapeutics
Windtree Therapeutics is a biotech company specializing in the development of drugs for the treatment of cardiovascular diseases in the intensive care setting. Its future depends on the success of clinical trials. This chart reflects the market's assessment of the likelihood of commercial success for its hospital-based drugs.
%20sales%20of%20the%20company%20Windtree%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Windtree-Therapeutics&v=1772513555376 "Schedule of future (projected) sales of the company Windtree Therapeutics")
Future (projected) sales of companies in the market segment - Heart
Windtree Therapeutics develops treatments for acute cardiovascular and pulmonary diseases. Its drugs are designed for use in intensive care settings. The chart shows forecasts for the cardiac pharmaceutical segment. The company's success depends on demonstrating the effectiveness of its drugs in life-threatening situations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772513555381 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Windtree Therapeutics develops drugs to treat critical cardiovascular diseases. The company is in clinical trials, and its success depends on their results. This timeline, reflecting the overall investment climate, affects the ability of biotech companies to attract funding for expensive and lengthy trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513555389 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Windtree Therapeutics
Windtree Therapeutics is a biotech company developing treatments for cardiovascular diseases, particularly in the critical care setting. The company is in clinical trials. This chart shows the financial costs involved in developing drugs that can save lives and be profitable.
Market segment marginality - Heart
Windtree Therapeutics develops drugs for the treatment of acute cardiovascular and pulmonary diseases. This chart shows the average profitability in the pharmaceutical industry. A focus on critical conditions, where there is a high unmet need, gives the company the potential to achieve high profitability if its clinical programs are successful.
Market marginality as a whole
Windtree Therapeutics is a biopharmaceutical company developing treatments for critical cardiovascular and respiratory diseases. It is currently in clinical trials. This total revenue chart vividly illustrates the difference between a business generating revenue today and a science-based company focused on saving lives tomorrow.
Employees in the company, segment and market as a whole
Number of employees in the company Windtree Therapeutics
Windtree Therapeutics is a biotech company specializing in developing treatments for critically ill cardiovascular diseases. This graph shows a small but highly qualified team. For a company at this stage, the staff consists of clinicians and scientists focused on conducting key trials.
Share of the company's employees Windtree Therapeutics within the market segment - Heart
Windtree Therapeutics specializes in critical care medications for critically ill patients with acute cardiovascular and pulmonary diseases. This is a narrow and complex niche. This chart shows the percentage of scientists and clinicians in this field the company attracts, reflecting its scientific focus and concentration of expertise in critical care medicine.
Number of employees in the market segment - Heart
Windtree Therapeutics, Inc. is a biotechnology company developing drugs for the treatment of acute cardiovascular and pulmonary diseases. The size of its small but focused clinical team reflects the stages of drug development. The increase in staff may be related to the preparation and execution of key phases of clinical trials.
Number of employees in the market as a whole
Windtree Therapeutics develops drugs to treat cardiorespiratory diseases in the intensive care setting. This graph shows the biotech company's clinical-stage progress. Its small staff of scientists and physicians is growing as research progresses. Success in trials will require a significant expansion of the team for commercialization.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Windtree Therapeutics (WINT)
Windtree Therapeutics develops treatments for cardiovascular and respiratory diseases. For a company in clinical development, this metric demonstrates the concentration of intellectual capital. Market value is based almost entirely on the potential of its drugs, not revenue. This is the valuation of patents based on a small team of scientists and doctors.
%20of%20the%20company%20Windtree%20Therapeutics%20(WINT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Windtree-Therapeutics-WINT&v=1772513555738 "Chart of market capitalization per employee (in thousands of dollars) of the company Windtree Therapeutics (WINT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Windtree Therapeutics develops treatments for acute cardiovascular diseases. Like many clinical-stage biotech companies, its value is determined by the prospects of its drugs. This chart shows how investors evaluate the company's scientific potential relative to its small team.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772513555751 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Windtree Therapeutics is a biopharmaceutical company focused on treating cardiovascular diseases in critical care settings. The chart shows the market's valuation in this niche area of medicine. It reflects how the market perceives the potential of their drugs to save lives in critical situations where the need for new medications is high.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513555794 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Windtree Therapeutics (WINT)
Windtree is a clinical-stage biotech company specializing in the treatment of acute cardiovascular diseases (e.g., cardiogenic shock). The company is not profitable. This chart shows the net loss (R&D costs) per employee working in critical care.
%20Chart%20Windtree%20Therapeutics%20(WINT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Windtree-Therapeutics-WINT&v=1772513555878 "Company Profit Per Employee (in thousands of dollars) Chart Windtree Therapeutics (WINT)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Windtree Therapeutics is a biotech company specializing in the development of drugs for the treatment of cardiopulmonary diseases. This graph shows the loss per employee during clinical trials. It serves as a benchmark for assessing how intensively the company invests in its R&D programs to bring critical care drugs to market.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772513555913 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Windtree Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cardiopulmonary diseases, particularly cardiogenic shock. The company is unprofitable. This chart shows the loss per employee, reflecting the R&D investment phase in drug discovery for critical conditions.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513555956 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Windtree Therapeutics (WINT)
Windtree Therapeutics is a biotech company specializing in critical care medications. This chart reflects its progress in commercialization. Increases in revenue per employee typically result from strategic partnerships or regulatory approval and launch of a niche product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Windtree-Therapeutics-WINT&v=1772513556011 "Sales chart per company employee Windtree Therapeutics (WINT)")
Sales per employee in the market segment - Heart
Windtree (WINT) is a clinical-stage biotech focused on treating cardiovascular and pulmonary diseases (heart failure). The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Employee productivity here would be zero.
Sales per employee for the market as a whole
Windtree is a biotech company specializing in cardiovascular diseases. During the clinical trial phase, revenue is minimal, but the R&D staff is large. This metric is important as a future indicator: if the drug is successful and approved, it will show how effectively the company will be able to commercialize its research.
Short shares by company, segment and market as a whole
Shares shorted by company Windtree Therapeutics (WINT)
Windtree Therapeutics (WINT) is a biotech company focused on critical care drugs, primarily for cardiovascular and pulmonary diseases (e.g., heart failure). This chart shows bearish bets. Bears doubt the success of their clinical trials or the commercial potential of their drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Windtree-Therapeutics-WINT&v=1772513556194 "Short Shares Chart for the Company Windtree Therapeutics (WINT)")
Shares shorted by market segment - Heart
Windtree Therapeutics is a biotech company specializing in developing treatments for acute cardiovascular and respiratory diseases. This is the critical care sector. This chart shows the total short position in the entire cardiac and pulmonary biotech sector. The rising indicator suggests investors are skeptical of this segment, possibly due to the high risks of clinical trials.
Shares shorted by the overall market
Windtree is a clinical-stage biotech focused on cardiovascular disease. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like WINT, preferring to cash out until the market calms down.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Windtree Therapeutics (WINT)
Windtree Therapeutics (WINT) is a biotech company focused on drugs for the treatment of critical cardiovascular diseases (e.g., cardiogenic shock). This chart measures the rate of price change. It helps identify when enthusiasm (above 70) about trial data or disappointment (below 30) peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Windtree-Therapeutics-WINT&v=1772513556366 "RSI 14 indicator chart for the company's stock Windtree Therapeutics (WINT)")
RSI 14 Market Segment - Heart
Windtree is a "biotech" company, a "savior" of the *heart* and *lungs*. They focus on *rare* cardiopulmonary diseases (heart failure). The "Heart" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It helps us understand: is WINT's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Windtree Therapeutics (WINT) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast WINT (Windtree Therapeutics)
Windtree Therapeutics is a biotech company developing drugs for the treatment of acute cardiovascular and respiratory diseases. This chart shows the average target price. Analysts' forecasts are based on an assessment of clinical data for its lead candidates (e.g., for cardiogenic shock) and their market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-WINT-Windtree-Therapeutics&v=1772513556520 "A chart showing analyst consensus forecasts for the expected stock price. WINT (Windtree Therapeutics)")
The difference between the consensus estimate and the actual stock price WINT (Windtree Therapeutics)
Windtree is a biotech R&D company focused on critical care drugs (heart failure, respiratory distress). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their "venture capital" assessment of the chances of success in this complex R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-WINT-Windtree-Therapeutics&v=1772513556582 "A chart showing the difference between the consensus forecast and the actual stock price. WINT (Windtree Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Heart
Windtree (WINT) is a biotech company focused on treating cardiovascular diseases, particularly cardiogenic shock. This is a high-risk R&D company. This chart shows analysts' overall expectations for the cardiology sector. It reflects whether experts believe breakthroughs in the treatment of acute cardiac conditions are possible.
Analysts' consensus forecast for the overall market share price
Windtree Therapeutics (WINT) is a clinical-stage biopharmaceutical company focused on treating cardiovascular and respiratory diseases. This is a high-risk research endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Windtree Therapeutics
Windtree is a biotech R&D company focused on saving the heart and lungs. Their R&D pipeline (Istaroxime, AEROSURF) targets acute heart failure and respiratory distress syndrome (RDS) in preterm infants. This chart is purely an R&D barometer. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Heart
Windtree (WINT) is a heart and lung biotech. They specialize in critical care conditions like cardiogenic shock and acute respiratory distress syndrome. They're a critical care pharma. This chart compares their composite index to the sector average, showing their position.
The AKIM Index for the overall market
Windtree Therapeutics is a biotech company focused on developing treatments for acute cardiovascular and pulmonary diseases (Istarxoxime). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is seeking funding for trials, stacks up against overall economic trends.
